PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107837
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2107837
Regenerative Medicine (Bone and Joint) Market is estimated to be valued at USD 10.3 Bn in 2026 and is expected to reach USD 21.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.3 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.00% | 2033 Value Projection: | USD 21.3 Bn |
Regenerative medicine is a biological heterogeneous domain that incorporates material science, engineering, medicine, biological science, and surgery. It acts therapeutically by augmenting and stimulating the body's capacity for regeneration and self-repair. Regenerative medicine involves the development of methods to regrow, repair or replace either the damaged or diseased cells, organs or tissues. This medicinal branch includes the generation and usage of stem cells and tissue engineering.
Moreover, Major players in the market are also focused on expanding their capabilities. For instance, in March 2020, BioStem Life Sciences, a subsidiary of BioStem Technologies Inc. and a developer of regenerative therapies, announced to add R&D laboratory to its Florida, U.S. facility.
Key companies focusing on product approvals in regenerative medicine is expected to drive the global regenerative medicine (Bone and Joint) market growth. For instance, in 2017, Karl Schumacher Dental, LLC launched its new range of regenerative products, which include allograft, xenograft, and synthetic and collagen membranes.
Moreover, adoption of 3D printing technology in regenerative medicine (bone and joint) is expected to aid in growth of the global regenerative medicine (bone and joint) market. For instance, in February 2020, researchers from Wake Forest School of Medicine, U.S. reported investigation of the effects of neural cell integration into the bioprinted skeletal muscle construct to accelerate functional muscle regeneration in vivo.
Furthermore, High prevalence of arthritis is expected to propel growth of the global regenerative medicine (bone and joint) market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC)'s May 2019 report, around 54.4 million U.S. adults had diagnosed arthritis, which accounted for around 1 in 4 people in the U.S.